Lipoprotein(a): Reloaded

Current Cardiovascular Risk Reports

Volumn 6, Issue 1, 2012, Pages 12-20

  Kronenberg, Florian ^a   Utermann, Gerd ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Apo(a); Apolipoprotein(a); Association study; Atherosclerosis; Cardiovascular risk factor; Causality; Copy number variation; Coronary heart disease; Genetic trait; Kidney disease; Lipoprotein metabolism; Lipoprotein(a); Lp(a); Mendelian Randomization; Multiallelic locus; Polymorphism

Indexed keywords

APOLIPOPROTEIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLASMINOGEN; TRANSFORMING GROWTH FACTOR BETA;

CARDIOVASCULAR DISEASE; CHROMOSOME 6Q; CLINICAL PRACTICE; COPY NUMBER VARIATION; CORONARY RISK; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LPA GENE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PULSED FIELD GEL ELECTROPHORESIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

EID: 84862573391     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-011-0216-y     Document Type: Review

References (69)

1. Berg K. A new serum type system in man - the Lp system. Acta Path Microbiol Scand. 1963; 59: 369-82.
2. Utermann G. The mysteries of lipoprotein(a). Science. 1989; 246: 904-10.
3. Dieplinger H, Utermann G. The seventh myth of lipoprotein(a): where and how is it assembled? Curr Opin Lipidol. 1999; 10: 275-83.
4. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004; 15: 167-74.
5. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993; 2: 933-40.
6. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 330: 132-7.
7. Lackner C, Boerwinkle E, Leffert CC, et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991; 87: 2153-61.
8. Kraft HG, Köchl S, Menzel HJ, et al. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet. 1992; 90: 220-30.
9. Jauhiainen M, Metso J, Koskinen P, Ehnholm C. Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. Biochem J. 1991; 274: 491-6.
10. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987; 80: 458-65.
11. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun. 1993; 191: 1192-6.
12. Erdel M, Hubalek M, Lingenhel A, et al. Counting the repetitive kringle-IV repeats in the gene encoding human apolipoprotein(a) by fibre-FISH [letter]. Nat Genet. 1999; 21: 357-8.
13. Kraft HG, Lingenhel A, Köchl S, et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996; 16: 713-9.
14. Geethanjali FS, Luthra K, Lingenhel A, et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis. 2003; 169: 121-30.
15. • Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009; 301: 2331-2339. This article reports the largest single study applying the "Mendelian Randomization" approach to demonstrate that the association of high Lp(a) with CHD is likely to be causal. They confirm that low K-IV copy number in LPA, which is associated with high Lp(a) levels in plasma, is also associated with risk for myocardial infarction. This is genetic evidence using the K-IV CNV for a causal role of Lp(a) in myocardial infarction.
16. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987; 330: 113-4.
17. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol. 1992; 136: 441-9.
18. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol. 1999; 10(2): 133-41.
19. Lamon-Fava S, Jimenez D, Christian JC, et al. The NHLBI Twin Study: heritability of apolipoprotein A-I and B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis. 1991; 91: 97-106.
20. Austin MA, Sandholzer C, Selby JV, et al. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet. 1992; 51: 829-40.
21. Scholz M, Kraft HG, Lingenhel A, et al. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet. 1999; 7: 169-78.
22. Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet. 2006; 14: 190-201.
23. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992; 90: 52-60.
24. Mooser V, Scheer D, Marcovina SM, et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet. 1997; 61: 402-17.
25. Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest. 1993; 91: 1630-6.
26. Puckey LH, Lawn RM, Knight BL. Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Hum Mol Genet. 1997; 6: 1099-107.
27. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991; 86: 607-14.
28. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet. 2001; 10: 815-24.
29. Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital Lp(a) deficiency: a frequent apo(a) 'null' mutation in Caucasians. Hum Mol Genet. 1999; 8: 2087-96.
30. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 2010; 3: 39-46.
31. • Tregouet DA, Konig IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009; 41(3): 283-285. The authors identify, by the first haplotype-based GWAS, a haplotype in the LPA genomic region that is associated with myocardial infarction. The haplotype built by two SNPs is associated with high Lp(a) levels but the association with myocardial infarction disappeared after correction for Lp(a) levels. This is genetic evidence using SNPs for a causal role of high Lp(a) in myocardial infarction.
32. • Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361: 2518-2528. In this large candidate gene -association study, the authors find SNPs in the LPA gene that are associated with risk for myocardial infarction. These SNPs are also associated with high Lp(a) and low K-IV copy number. Also, this study provides genetic evidence for a causal role of high Lp(a) as a risk factor for CHD.
33. Dumitrescu L, Glenn K, Brown-Gentry K, et al. Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey. PLoS One. 2011; 6: e16604.
34. Trommsdorff M, Köchl S, Lingenhel A, et al. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest. 1995; 96: 150-7.
35. Mooser V, Mancini FP, Bopp S, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet. 1995; 4: 173-81.
36. Chretie JP, Coresh J, Berthier-Schaad Y, et al. Three single-nucleotide polymorphisms in LPA account for the majority of lipoprotein(A) level elevation in African Americans compared to European Americans. J Med Genet. 2006; 43: 917-23.
37. • Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS ONE. 2011; 6: e14581. The authors of this study use an ancestry-based approach (considering the degree of admixture in African Americans) to identify variation in the LPA gene that explains the differences in Lp(a) levels between African Americans and Europeans.
38. Kraft HG, Lingenhel A, Pang RWC, et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: The distribution of null alleles is non-random. Eur J Hum Genet. 1996; 4: 74-87.
39. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996; 37: 2569-85.
40. Crawford DC, Peng Z, Cheng JF, et al. LPA and PLG Sequence Variation and Kringle IV-2 Copy Number in Two Populations. Hum Hered. 2008; 66: 199-209.
41. Kraft HG, Lingenhel A, Raal FJ, et al. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 522-8.
42. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996; 27: 1-25.
43. • Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-423. The largest meta-analysis of prospective studies relating Lp(a) levels to CHD risk. Risk increases continuously with Lp(a) levels without evidence for a threshold.
44. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet. 1986; 1: 507-8.
45. Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: Evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992; 89: 1040-6.
46. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992; 12: 1214-26.
47. •• Erqou S, Thompson A, Di AE, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J Am Coll Cardiol. 2010; 55: 2160-2167. This is the first meta-analysis of studies relating apo(a) isoform size or genomic variation in K-IV copy number to CHD and stroke. As most single studies included in the meta-analysis found a significant association with CHD, they observe a strong association of short isoforms/low K-IV copy numbers with CHD with a doubling in risk. The association with stroke was also significant but much weaker.
48. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscler Thromb Vasc Biol. 2000; 20: 2619-24.
49. Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2030-6.
50. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2008; 203(2): 371-6.
51. Ober C, Nord AS, Thompson EE, et al. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res. 2009; 50: 798-806.
52. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc Natl Acad Sci U S A. 1994; 91: 2130-4.
53. Linton MF, Farese RV, Chiesa G, et al. Transgenic Mice Expressing High Plasma Concentrations of Human Apolipoprotein B100 and Lipoprotein(a). J Clin Invest. 1993; 92: 3029-37.
54. Fan J, Araki M, Wu L, et al. Assembly of lipoprotein (a) in transgenic rabbits expressing human apolipoprotein (a). Biochem Biophys Res Commun. 1999; 255: 639-44.
55. Lawn RM, Wade DP, Hammer RE, et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 1992; 360: 670-2.
56. Mancini FP, Newland DL, Mooser V, et al. Relative contributions of apolipoprotein(a) and apolipoprotein- B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol. 1995; 15: 1911-6.
57. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005; 258: 94-114.
58. •• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23): 2844-2853. This is a consensus statement written by a panel of the European Atherosclerosis Society. It gives clinical recommendations on Lp(a) in primary and secondary prevention of CHD.
59. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 998-1006.
60. • Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009; 6: 229-239. The authors report an observational study describing the effect of LDL apheresis in patients with severe coronary disease and excessively high Lp(a) levels on major coronary events. In a subgroup of their patients, all LDL was present in Lp(a) already before apheresis due to aggressive conventional lipid-lowering therapy. Analysis of this subgroup currently presents the most compelling evidence that lowering Lp(a) prevents major coronary events in high-risk individuals.
61. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol. 2010; 21: 487-91.
62. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol. 2007; 27: 661-70.
63. Kamstrup PR, Benn M, Tybaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008; 117: 176-84.
64. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990; 322: 1494-9.
65. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004; 256: 482-90.
66. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000; 11: 105-15.
67. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007; 71: 1036-43.
68. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007; 18: 1246-61.
69. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999; 10: 1027-36.